Kenya is seeking to boost its pharmaceutical manufacturing sector by targeting the wider East African market. The country aims to increase local production of essential medicines and medical supplies while reducing reliance on imports. To achieve this, manufacturers, regulators, and investors will meet at the African Healthcare Manufacturing Trade Exhibition and Conference (AHMTEC) in Nairobi. The summit will explore opportunities for expanding production and cross-border trade.
The Kenyan government's push is anchored in its target of producing at least 50 per cent of essential health products locally by 2026. The Ministry of Health's Local Manufacturing Strategy 2026–2030 seeks to encourage domestic pharmaceutical companies to move beyond basic fill-finish operations towards more complex and higher-value manufacturing. However, expanding production will require access to larger markets to make investments commercially sustainable.
Regional integration and regulatory harmonization are critical to strengthening Kenya's pharmaceutical industry. A key issue expected to dominate the summit is the harmonization of medicine regulation through the African Medicines Agency (AMA). This could simplify product approvals and reduce barriers for pharmaceutical companies seeking to sell across African markets.
The discussions will also examine opportunities to expand local production of active pharmaceutical ingredients (APIs) and diagnostics. These areas are considered critical to reducing vulnerabilities in medical supply chains. The summit will bring together pharmaceutical manufacturers, policymakers, regulators, investors, and other industry players to explore opportunities for expanding production and cross-border trade.
AHMTEC 2026 will be co-hosted by the Federation of African Pharmaceutical Manufacturers Associations (FAPMA), Vizuri Health Dynamics, and EPMSMISA, in partnership with Health 4 Development. The conference will focus on policy and investment incentives, regulatory harmonization, and development of local API manufacturing capacity. Industry players will also use the African Manufacturing Market Intelligence & Network Analysis (AMMINA) database to identify potential business and trade partnerships.
The AMMINA database currently tracks more than 750 health manufacturers and over 2,500 products across the continent. This provides market intelligence that can help connect manufacturers with potential regional opportunities. AHMTEC has previously been used as a platform for major healthcare manufacturing initiatives, including the launch of Unitaid's $50 million regional manufacturing portfolio targeting essential HIV, malaria, and maternal health treatments.
For Kenya, access to the wider regional market could provide manufacturers with the scale needed to justify investment in more sophisticated production facilities. The summit is expected to bring together industrial policy and commercial considerations, including how regulatory systems, procurement practices, financing, and regional trade can work together to create a stronger market for locally produced medicines and medical supplies.
Key points
- Kenya aims to produce at least 50 per cent of essential health products locally by 2026.
- Regional regulatory harmonization is critical to strengthening Kenya's pharmaceutical industry.
- AHMTEC 2026 will focus on policy and investment incentives, regulatory harmonization, and development of local API manufacturing capacity.
